- Home
- Applications
- europe
- development and clinical
Show results for
Refine by
Development And Clinical Product Applications In Europe
8 applications found
BOC Sciences is committed to supplying cost-effective products and services. We provide Choline Fenofibrate (Cas No:856676-23-8). More information, please visit the website: http://www.bocsci.com/choline-fenofibrate-cas-856676-23-8-item-84-259938.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Iconeus is leveraging its expertise in preclinical research to develop innovative clinical applications using its Iconeus One CR functional ultrasound system. ...
ByIconeus based in Paris, FRANCE
Comprehensive antibody reactivity profiling: validate specificity, identify cross-reactions. The issue of antibody cross-reactivity is one that has often been often overlooked or sidelined in the past, with typical antibody QC involving evidence of binding to the intended target, while neglecting potential cross-reactivity. In recent years, however, many examples have come to light where poor validation of antibodies has led to misleading or erroneous conclusions for assays in which they are used as reagents, due ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
We believe that this approach is superior to others being pursued and provides the company with numerous competitive advantages, including: de-risking of clinical programmes based on IMT precedence, accelerated clinical development and opportunities to discover second and third generation products through data generated from clinical ...
ByEnteroBiotix Ltd based in Glasgow, UNITED KINGDOM
The use of probiotics is a very promising alternative for the prevention and/or treatment of multiple health issues, in both humans and animals. By modifying the composition of the microbiota with probiotics, we may help to mitigate and solve upper respiratory, genitourinary or gastrointestinal tracts and periodontal infections, as well as dysbiosis issues related to fertility, premature births, dermatology, autoimmune diseases, and many more. The key is to choose the appropriate strain and dosage for each ...
ByZinereo Pharma based in Pontevedra, SPAIN
2A Pharma’s vaccine platform is based on mutated parvoviral particles consisting essentially of one protein. The particles contain no viral genome and are replicative defective and non-pathogenic. The particle capsid surface has repetitive, immunogenic sites, where peptides of interest can be inserted and allows us to generate monovalent or bivalent vaccines as required. Each peptide of interest will be presented 60 times on the capsid surface and both the innate and adaptive immune systems are activated to ...
By2A Pharma ApS based in Aalborg Øst, DENMARK
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)